Look here for updates on publications and other news

David Fruman was elected as a AAAS Fellow in 2016. The UCI press release is here.

Our recent study of rapamycin mechanism in lymphocytes was published in Science Signaling in May 2016:

So, L, Lee, J, Palafox, M, Mallya, S, Woxland, C, Arguello, M, Truitt, M, Sonenberg, N, Ruggero, D, Fruman, DA. The 4E-BP/eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes. 2016. Science Signaling, 9: ra57.

Check out additional recent reviews and research papers in Cell, Molecular Cancer Therapeutics, Frontiers in Immunology, Journal of Immunology, New England Journal of Medicine, Nature Reviews Drug Discovery, Cancer Discovery, PNAS, and Oncotarget:

Fruman, DA, Chiu, H, Hopkins, BD, Bagrodia, S, Cantley, LC, Abraham, RT. The PI3K pathway in human disease. 2017. Cell, 170: 605-635.

Vo, TT, Lee, JS, Nguyen, D, Lui, B, Pandori, W, Khaw, A, Mallya, S, Lu, M, Müschen, M, Konopleva, M, Fruman, DA. mTORC1 inhibition induces resistance to methotrexate and 6-mercaptopurine in Ph+ and Ph-like B-ALL. 2017. Mol. Cancer Therap., Epub May 31.

Chiu, H, Mallya, S, Nguyen, P, Mai, A, Winkler, DG, McGovern, K, Kutok, JL, Fruman, DA. The selective PI3K p110d inhibitor IPI-3063 potently suppresses B cell survival, proliferation and differentiation. 2017. Front. Immunol., 8: 747.

Pai, C, Walsh, CM, Fruman, DA. Context-specific function of S6K2 in helper T cell differentiation. 2016. J. Immunol., 197: 3049-58.

Lee, JS, Vo, TT, Fruman, DA. Targeting mTOR for the treatment of B cell malignancies. Br. J. Clin. Pharmacol., Epub Jan. 25.

Vo, TT, Fruman, DA. INPP4B is a tumor suppressor in the context of PTEN deficiency. 2015. Cancer Discov. 5: 697-700.

Lee, JS, Tang, SS, Ortiz, V, Vo, TT, Fruman, DA. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. 2015. Oncotarget, 6: 35202-17.

Fruman, DA, Cantley, LC. Idelalisib: a PI3K delta inhibitor for B cell malignancies. 2014. New Engl. J. Med., 370: 1061-2.

Fruman, DA, Rommel, C. PI3K and cancer: lessons, challenges, and opportunities. 2014. Nat. Rev. Drug Discov., 13:140-56.

Beagle, BR, Nguyen, D, Mallya, S, Tang, SS, Lu, M, Zeng, A, Konopleva, M, Vo, TT, Fruman, DA. mTOR inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. 2015. Oncotarget, 6: 2088-100.

Limon, JJ, So, L, Jellbauer, S, Chiu, H, Corado, J, Sykes, S, Raffatellu, M, Fruman, DA. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. 2014. PNAS, 111:E5076-85.

 

David Fruman obtained a NIH-BEST award for professional development of UCI graduate students and postdocs:

http://sites.bio.uci.edu/2014/10/uci-receives-nih-grant-improve-options-doctoral-graduates-across-science-related-careers/

Trang Vo, postdoctoral fellow, was awarded a NIH F32 fellowship starting in July 2014.

David Fruman is quoted in a HealthDay news article about the PI3K delta inhibitor results reported in New England Journal:

http://health.usnews.com/health-news/articles/2014/03/12/experimental-drug-may-boost-leukemia-survival-without-chemo

Posted in News | Leave a comment